These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

270 related articles for article (PubMed ID: 33610957)

  • 1. Reduction of the risk of PML in natalizumab treated MS patients in Sweden: An effect of improved PML risk surveillance.
    Kågström S; Fält A; Berglund A; Piehl F; Olsson T; Lycke J
    Mult Scler Relat Disord; 2021 May; 50():102842. PubMed ID: 33610957
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis.
    Wijburg MT; Kleerekooper I; Lissenberg-Witte BI; de Vos M; Warnke C; Uitdehaag BMJ; Barkhof F; Killestein J; Wattjes MP
    JAMA Neurol; 2018 Jul; 75(7):827-833. PubMed ID: 29532061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Course of neuropsychological impairment during natalizumab-associated progressive multifocal leukoencephalopathy.
    Kinner M; Prehn C; Schneider R; Schroeder C; Kolb E; Gold R; Hoepner R; Chan A
    Eur J Neurol; 2021 Mar; 28(3):921-927. PubMed ID: 33085811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Progressive Multifocal Leukoencephalopathy Incidence and Risk Stratification Among Natalizumab Users in France.
    Vukusic S; Rollot F; Casey R; Pique J; Marignier R; Mathey G; Edan G; Brassat D; Ruet A; De Sèze J; Maillart E; Zéphir H; Labauge P; Derache N; Lebrun-Frenay C; Moreau T; Wiertlewski S; Berger E; Moisset X; Rico-Lamy A; Stankoff B; Bensa C; Thouvenot E; Heinzlef O; Al-Khedr A; Bourre B; Vaillant M; Cabre P; Montcuquet A; Wahab A; Camdessanché JP; Tourbah A; Guennoc AM; Hankiewicz K; Patry I; Nifle C; Maubeuge N; Labeyrie C; Vermersch P; Laplaud DA;
    JAMA Neurol; 2020 Jan; 77(1):94-102. PubMed ID: 31479149
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry.
    Prosperini L; de Rossi N; Scarpazza C; Moiola L; Cosottini M; Gerevini S; Capra R;
    PLoS One; 2016; 11(12):e0168376. PubMed ID: 27997580
    [TBL] [Abstract][Full Text] [Related]  

  • 6. JCPyV microRNA in plasma inversely correlates with JCPyV seropositivity among long-term natalizumab-treated relapsing-remitting multiple sclerosis patients.
    Basnyat P; Virtanen E; Elovaara I; Hagman S; Auvinen E
    J Neurovirol; 2017 Oct; 23(5):734-741. PubMed ID: 28831768
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Changes in Anti-JCV Antibody Status in a Large Population of Multiple Sclerosis Patients Treated with Natalizumab.
    Sgarlata E; Chisari CG; D'Amico E; Millefiorini E; Patti F
    CNS Drugs; 2020 May; 34(5):535-543. PubMed ID: 32221861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.
    Ho PR; Koendgen H; Campbell N; Haddock B; Richman S; Chang I
    Lancet Neurol; 2017 Nov; 16(11):925-933. PubMed ID: 28969984
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PML risk is the main factor driving the choice of discontinuing natalizumab in a large multiple sclerosis population: results from an Italian multicenter retrospective study.
    Chisari CG; Comi G; Filippi M; Paolicelli D; Iaffaldano P; Zaffaroni M; Brescia Morra V; Cocco E; Marfia GA; Grimaldi LM; Inglese M; Bonavita S; Lugaresi A; Salemi G; De Luca G; Cottone S; Conte A; Sola P; Aguglia U; Maniscalco GT; Gasperini C; Ferrò MT; Pesci I; Amato MP; Rovaris M; Solaro C; Lus G; Maimone D; Bergamaschi R; Granella F; Di Sapio A; Bertolotto A; Totaro R; Vianello M; Cavalla P; Bellantonio P; Lepore V; Patti F;
    J Neurol; 2022 Feb; 269(2):933-944. PubMed ID: 34181077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Longitudinal JCV serology in multiple sclerosis patients preceding natalizumab-associated progressive multifocal leukoencephalopathy.
    Vennegoor A; van Rossum JA; Polman CH; Wattjes MP; Killestein J
    Mult Scler; 2015 Oct; 21(12):1600-3. PubMed ID: 25662344
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-reconstitution Inflammatory Syndrome in Multiple Sclerosis Patients Treated With Natalizumab: A Series of 4 Cases.
    N'gbo N'gbo Ikazabo R; Mostosi C; Quivron B; Delberghe X; El Hafsi K; Lysandropoulos AP
    Clin Ther; 2016 Mar; 38(3):670-5. PubMed ID: 26856928
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced expression of L-selectin in T-cells correlates with relative lymphocyte increase in patients with RRMS treated with natalizumab - functional implication towards PML risk.
    Boziki MK; Karapanayotides T; Papadopoulos G; Lagoudaki R; Melo P; Bakirtzis C; Nikolaidis I; Gounari E; Tsavdaridou V; Skoura L; Afrantou T; Tatsi T; Grigoriadou E; Polyzoidou E; Mandoras N; Giantzi V; Kalogera-Fountzila A; Ioannidis P; Parissis D; Pelidou SH; Zoidou S; Grigoriadis N
    Neurol Res; 2020 Mar; 42(3):209-221. PubMed ID: 32048570
    [No Abstract]   [Full Text] [Related]  

  • 13. Asymptomatic Progressive Multifocal Leukoencephalopathy Associated with Natalizumab: Diagnostic Precision with MR Imaging.
    Hodel J; Outteryck O; Dubron C; Dutouquet B; Benadjaoud MA; Duhin E; Verclytte S; Zins M; Luciani A; Rahmouni A; Pruvo JP; Vermersch P; Leclerc X
    Radiology; 2016 Mar; 278(3):863-72. PubMed ID: 26436861
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Matrix metalloproteinase 9 is decreased in natalizumab-treated multiple sclerosis patients at risk for progressive multifocal leukoencephalopathy.
    Fissolo N; Pignolet B; Matute-Blanch C; Triviño JC; Miró B; Mota M; Perez-Hoyos S; Sanchez A; Vermersch P; Ruet A; de Sèze J; Labauge P; Vukusic S; Papeix C; Almoyna L; Tourbah A; Clavelou P; Moreau T; Pelletier J; Lebrun-Frenay C; Montalban X; Brassat D; Comabella M;
    Ann Neurol; 2017 Aug; 82(2):186-195. PubMed ID: 28681388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Natalizumab continuation versus switching to ocrelizumab after PML risk stratification in RRMS patients: a natural experiment.
    Muñoz-Vendrell A; Arroyo-Pereiro P; León I; Bau L; Matas E; Martínez-Yélamos A; Martínez-Yélamos S; Romero-Pinel L
    J Neurol; 2023 May; 270(5):2559-2566. PubMed ID: 36913038
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lessons learned after 20 years of real-world experience with natalizumab.
    Khatri BO; Olapo T; Beals S; Lindman E; Perea T; Van Zealand P; Metzger RR
    Mult Scler Relat Disord; 2023 Dec; 80():105048. PubMed ID: 37866023
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort.
    Wijburg MT; Warnke C; Barkhof F; Uitdehaag BMJ; Killestein J; Wattjes MP
    J Neurol Neurosurg Psychiatry; 2019 Jan; 90(1):44-46. PubMed ID: 30100552
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of natalizumab-associated progressive multifocal leukoencephalopathy.
    Bloomgren G; Richman S; Hotermans C; Subramanyam M; Goelz S; Natarajan A; Lee S; Plavina T; Scanlon JV; Sandrock A; Bozic C
    N Engl J Med; 2012 May; 366(20):1870-80. PubMed ID: 22591293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring the John Cunningham virus throughout natalizumab treatment in multiple sclerosis patients.
    Domínguez-Mozo MI; García-Montojo M; Arias-Leal A; García-Martínez Á; Santiago JL; Casanova I; Galán V; Arroyo R; Fernández-Arquero M; Alvarez-Lafuente R
    Eur J Neurol; 2016 Jan; 23(1):182-9. PubMed ID: 26498276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Four cases of natalizumab-related PML: a less severe course in extended interval dosing?
    Scarpazza C; De Rossi N; Tabiadon G; Turrini MV; Gerevini S; Capra R
    Neurol Sci; 2019 Oct; 40(10):2119-2124. PubMed ID: 31175467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.